Number of drug resistance mutations (n pts) Months on ART Sex VL at study enrollment
(copies/mL)
CD4 at study enrollment (cells/mm3) NNRTI NRTI
≥5 (n=8 pts)            
1* 48 F 3 010 524 K101E+V108I+Y181C D67N+K70R+M184V+K219E
2** 49 F 2 680 213 K101H+K103N+V106M+G190A+F227L D67N+M184V
3*,^ 41 F 4 310 354 K101E+V106M+G190A D67N+M184V
4 44 F 75 000 89 K103N+P225H D67N+K70R+M184V+T215F+K219E
5* 22 F 1 850 342 K103N+V108I A62V+V75I+M184V
6* 45 F 773 384 V106M+G190A M41L+D67N+K70R+M184V
7* 44 F 2 530 199 V106M+Y188LH D67N+M184V+ K219E
8 45 F 18 200 496 V106M+Y188L M41L+D67N+K70R+ M184V+T215Y
4 (n=6 pts)            
9 15 F 16 900 160 K101E+V108I+G190A M184V
10 45 F 11 000 464 K101H+K103N+G190A M184V
11 46 F 3 000 354 K103N+P225H V75I+M184V
12* 37 M 49 900 16 K103N+Y181C+P225H M184I
13^ 47 F 54 700 419 K103N+G190A+P225H M184V
14 47 F 9 670 377 K103N+V106A+G190A K65R
3 (n=10 pts)            
15* 48 F 18 300 331 K101E+Y188L M184I
16 13 F 6 890 214 K101E+V106M M184V
17 41 F 5 340 319 K103N D67N+M184V
18* 46 F 407 269 K103N+P225H M184V
19 47 F 6 510 190 K103N+V108I M184V
20* 47 F 1 330 277 K103N+V108I M184V
21 47 M 31 000 99 K103N+V108I M184V
22** 47 F 1 280 642 K103N+V106M M184V
23* 40 F 955 276 V106M A62V+M184V
24 84 F 43 800 174 V106M+Y188C M184V
2 (n=2 pts)            
25 43 M 430 151 K103N M184V
26**,^ 47 F 1 370 320 K103N M184V
1 (n=5 pts)            
27** 44 M 178 000 47 K103N ---
28** 46 F 56 500 187 K103N ---
29** 45 F 42 800 100 K103N ---
30* 45 M 1 130 439 K103N ---
31^ 46 F 43 900 193 K103N ---

32

46

F

552

369

No major mutations

No major mutations

33**

41

F

882 000

90

No major mutations

No major mutations

34**

47

F

1 450

192

No major mutations

No major mutations

35*,^

43

M

83 000

103

No major mutations

No major mutations

36^

47

F

77 500

232

No major mutations

No major mutations

37**,^

43

M

312 000

203

No major mutations

No major mutations

38^

50

M

493 000

157

No major mutations

No major mutations

Not amplifiable (n=5 pts)

 

 

 

 

 

 

39

44

F

463

357

---

---

40*,^

43

F

4 660

554

---

---

41**,^

41

M

1 060

430

---

---

42**

13

F

557

445

---

---

43**

55

F

66 800

379

---

---

Pts, patients; F, female; M, male; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI, VL: virus load; *Persistent virologic failure at follow-up; ** Re-suppressed at follow-up; ^ Came late >7 days for the last drug-refill visit
Table 2: Patterns of reverse transcriptase drug resistance mutations
Goto home»